ECOR
electroCore, Inc.
There isn't enough reported data to score ECOR yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
ECOR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
ECOR's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ECOR PE Valuation
ECOR has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
ECOR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect ECOR's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ECOR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$1.68 | +$0.01 |
| Q2 2025 | -$1.59 | +$0.47 |
| Q1 2025 | -$1.53 | +$1.18 |
| Q4 2024 | -$1.59 | +$1.83 |
| Q3 2022 | -$4.50 | +$0.45 |
| Q2 2022 | -$4.20 | +$1.35 |
| Q1 2022 | -$3.90 | +$2.70 |
| Q4 2021 | -$4.35 | +$4.65 |
OSCR has the stronger earnings trend. Trailing diluted EPS is down 199% for ECOR versus OSCR up 147%.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ECOR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $9.7M | +12% |
| Q2 2026 | $9.5M | +28% |
| Q1 2026 | $9.6M | +43% |
| Q4 2025 | $9.2M | +31% |
| Q3 2025 | $8.7M | +33% |
| Q2 2025 | $7.4M | +20% |
| Q1 2025 | $6.7M | +23% |
| Q4 2024 | $7M | +36% |
ECOR's revenue has grown year over year every quarter since late 2020: $10M last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -16% | +17 points |
| Q2 2026 | -29% | +18 points |
| Q1 2026 | -55% | +1.4 points |
| Q4 2025 | -32% | +12 points |
| Q3 2025 | -33% | +7.3 points |
| Q2 2025 | -48% | -5.3 points |
| Q1 2025 | -57% | +14 points |
| Q4 2024 | -44% | +33 points |
ECOR's operating margin was −16% last quarter, up 17 points from the same quarter a year ago, near the top of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ECOR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over ECOR on profitability, with a higher operating margin.
ECOR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2.8M | -$1.2M |
| Q2 2026 | -$3.5M | -$2.9M |
| Q1 2026 | -$3M | +$1.4M |
| Q1 2025 | -$4.4M | -$1.8M |
| Q1 2024 | -$2.6M | +$3.3M |
| Q4 2023 | -$3.2M | +$850K |
| Q3 2023 | -$2.4M | +$2.2M |
| Q1 2023 | -$5.9M | -$1.1M |
ECOR has burned cash in almost every quarter: −$11M over the past year, against −$9M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ECOR on cash generation, producing positive trailing cash flow while its opponent burns cash.
ECOR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +33% | +2.5M shares |
| 1 year | +50% | +3.3M shares |
| 3 years | +283% | +7.4M shares |
ECOR has 10M diluted shares, up 50% from a year ago.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over ECOR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ECOR Net Leverage
ECOR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
ECOR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.8 | Neutral |
| Stochastic | 17.3 | Oversold |
ECOR's weekly RSI is 39 (neutral) and its Stochastic is 17 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ECOR PE vs Healthcare Sector
ECOR has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ECOR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.23 | 36% below |
| 20 week MA | $8.41 | 37% below |
| 50 week MA | $7.30 | 28% below |
| 100 week MA | $7.79 | 32% below |
| 200 week MA | $7.05 | 25% below |
ECOR is in a downtrend: it's below all five of its weekly moving averages, and 25% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ECOR on trend strength, trading above more of its moving averages.
ECOR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.7 | $24.2 | +23% |
| 2021 | $24.2 | $10.4 | -57% |
| 2022 | $10.4 | $4.61 | -56% |
| 2023 | $4.61 | $5.95 | +29% |
| 2024 | $5.95 | $16.5 | +177% |
| 2025 | $16.5 | $4.95 | -70% |
| 2026 YTD | $4.95 | $5.29 | +6.9% |
ECOR's yearly returns have swung widely, from +177% in 2024 to −70% in 2025. It's up 6.9% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ECOR on returns for 2026, with the stronger performance.